Acquisitions - Additional Information (Details)	1 Months Ended			3 Months Ended	12 Months Ended
	Jul. 31, 2021 USD ($) shares	Feb. 28, 2021 USD ($) Milestone	Sep. 30, 2016 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 01, 2021 USD ($)	Aug. 31, 2017 USD ($)
Humabs
Business Acquisition [Line Items]
Sales milestone achieved					$ 60,000,000.0
Humabs | HBV Product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events, maximum							$ 135,000,000.0
Estimated fair value, Remaining contingent consideration				$ 16,100,000
Humabs | Another Product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events, maximum							$ 105,000,000.0
Humabs | SARS-CoV-2 Product
Business Acquisition [Line Items]
Regulatory milestones achieved					35,000,000.0
Sales milestone achieved					$ 60,000,000.0
TomegaVax
Business Acquisition [Line Items]
Minimum common stock conversion price for milestone payments consideration | $ / shares			$ 90
Common stock shares Issued for milestone payment| shares | shares	42,737
Value of common stock shares Issued for milestone payment	$ 1,900,000
Payment made for asset acquisition milestone						$ 8,100,000
TomegaVax | Clinical Development [Member]
Business Acquisition [Line Items]
Minimum common stock conversion price for milestone payments consideration | $ / shares			$ 45
TomegaVax | TomegaVax Letter Agreement
Business Acquisition [Line Items]
Milestone payments aggregate amount payable, maximum			$ 30,000,000.0
Minimum common stock conversion price for milestone payments consideration | $ / shares			$ 45
Milestone payments related terms				the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company’s publicly traded common stock, or implied price per share of the Company’s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company’s clinical development at the time of the relevant event triggering the payment.
Number of milestones achieved | Milestone		1
Asset acquisition contingent consideration liability		$ 10,000,000.0
Estimated fair value of embedded derivative				$ 2,800,000
TomegaVax | Maximum
Business Acquisition [Line Items]
Remaining payment for asset acquisition milestone, maximum						$ 20,000,000.0